Home » Isomorphic Labs Maps $5 Billion to Clinical Trials and AI Infrastructure

Isomorphic Labs Maps $5 Billion to Clinical Trials and AI Infrastructure

By

–

Isomorphic Labs Maps $5 Billion to Clinical Trials and AI Infrastructure

LONDON, November 17, 2026 — Isomorphic Labs has closed a $5 billion Series C round to scale its AI drug design engine and build the clinical infrastructure needed to move its pipeline toward human trials. The financing, co-led by Greenoaks and Sequoia Capital, marks the largest single investment yet in the Alphabet spinout’s bid to turn computational breakthroughs into approved medicines.

The Shift Is Capital Intensity

The company raised $600 million in its first external round in March 2025, followed by a $2.1 billion Series B in May 2026. The new capital arrives six months after the Series B, a pace that signals the shift is moving from pure research to the expensive work of clinical translation and global infrastructure build-out.

Co-leads Greenoaks and Sequoia Capital were joined by Andreessen Horowitz, Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. Alphabet continued its significant investment in the round, maintaining the deep ties that date back to Isomorphic’s founding as a DeepMind spinout in 2021. The company did not disclose its valuation, though Bloomberg reported this month that the round would value Isomorphic at about $50 billion.

IsoDDE and the Compute Pipeline

The proceeds target three fronts: further development of the Isomorphic Drug Design Engine (IsoDDE), expansion into new areas of biology, and global infrastructure for AI-led bioengineering. IsoDDE operates as a collection of AI simulation models built to handle different therapeutic areas and drug types. The system searches chemical space to design and refine molecules with drug-like properties, while proprietary agents navigate and reason through complex biology.

server room aisle with metal equipment racks
Photo: İsmail Enes Ayhan / Unsplash (Unsplash License)

In a February 2026 technical report, the company said IsoDDE doubled the performance of AlphaFold 3 on a protein-ligand structure prediction generalization benchmark. It predicts small molecule binding affinities with higher accuracy than physics-based methods at a fraction of the time and cost, and identifies new binding pockets on target proteins using only the amino acid sequence. The engine operates across multiple modalities, including proteins, small molecules, and antibodies.

Sequoia partner Konstantine Buhler cited scaling laws for Isomorphic’s models, where performance improves with more computing power and data. CEO Max Jaderberg estimates drug discovery needs roughly half a dozen AlphaFold-level breakthroughs stitched into a single machine. On compute supply, Hassabis told Bloomberg the company has “very secure compute pipelines,” noting that Google designs its own AI chips.

Pipeline Scaling Across Oncology and Immunology

Isomorphic now has more than 20 programs underway across oncology and immunology. The company reports positive preclinical outcomes from wholly owned programs and from partnered work, providing the basis for its planned move toward clinical trials. Hassabis stated the goal is to build a platform to do hundreds of drugs a year. The company expects to move beyond small-molecule drugs into “pretty much all modalities,” including large-molecule biologics.

In January 2026, Hassabis said Isomorphic expected its first clinical trials by the end of 2026. He would not give Bloomberg an updated target this week, saying the company is on track with its regulatory submissions and will have more to announce in 2027. No regulator has yet approved an AI-designed drug.

Pharma Partnerships Expand Across Modalities

The partnership portfolio spans the industry’s largest players. Eli Lilly collaborates on small-molecule therapeutics against undisclosed targets. Novartis began working with Isomorphic in January 2024 on small molecules against three challenging targets and expanded the agreement in February 2025 with up to three additional research programs. Johnson & Johnson joined in January 2026 for a cross-modality, multi-target research campaign spanning small molecules and biologics.

Jaderberg has described these partnerships as a discipline mechanism, bringing in “literally the industry’s hardest problems” and preventing the company from marking its own homework. The collaborations give Isomorphic a portfolio that pairs company-owned oncology and immunology work with partnered research across different drug modalities.

AlphaFold 3 Commercialization Path

AlphaFold 3, released in May 2024 by Google DeepMind and Isomorphic Labs, improved accuracy in modeling protein interactions and expanded modeling capabilities beyond proteins to DNA, RNA, and ligands. The platform was developed by training on approximately 100,000 protein structures and has identified the structure of over 200 million proteins, nearly all known to researchers. As of December 2025, it has been used by more than 3.3 million researchers from over 190 countries.

The commercialization of AlphaFold 3 runs through the Isomorphic platform. The foundational model feeds the understanding front of IsoDDE, which builds models of how proteins, DNA, and RNA fit together into signaling pathways and how disease rewires them. The design front then takes that understanding and generates an intervention across small molecules, antibodies, and peptides.

Building Clinical Infrastructure

Isomorphic is creating translational and clinical-development infrastructure to move research toward patient testing and support candidates approaching trials. The company appointed Dr. Ben B. Wolf as chief medical officer in June 2025 and operates offices in London, Lausanne, and Cambridge, Massachusetts. The central test for the Series C capital is whether reported preclinical progress translates into clinical evidence as candidates from owned and partnered programs enter human trials.

Hassabis told Bloomberg the round enables the company to accelerate progress: building foundational biology models, deepening systemic disease understanding, and driving first therapeutic programs toward clinical trials to deliver tangible impact for patients.

Sources

Photo: Terry Vlisidis / Unsplash (Unsplash License)

Get breaking stories first on our Telegram channel.

More stories by

Most read

AI Tools

Artificial Intelligence

Business

World News